Yahoo MoviesWriters of Color Creating Their Space, Gabby Rivera | MAKERS
Writers of Color Creating Their Space, Gabby Rivera | MAKERS
Writers of Color Creating Their Space, Gabby Rivera | MAKERS
ResumeEdge.com Writes Job-Winning Resumes to Help You Secure the Job.Lewes, DE, April 20, 2021 (GLOBE NEWSWIRE) -- Gone are the days when people had to spend hours making a perfect resume. Now there is a wide range of resume writing companies in the market offering remarkable help to each client. In this regard, ResumeEdge.com is one of the best and veteran resume writing companies committed to helping people in attaining their determined goals and ambitions. ResumeEdge.com started around 23 years ago with the intent to deliver top-notch and unique resumes to its clients. ResumeEdge family comprises professional and certified resume writers with experience in more than 40 different industries. They all work directly with clients via message board to craft excellent and job-winning resumes. The writers have created more than 100,000 resumes with around 98% customer satisfaction. The company helps its clients by delivering the finest resumes, thank you letters, and cover letters. Moreover, it also offers appealing LinkedIn profiles designed to attract hiring managers. The company believes that each individual is unique, so their resume should showcase their unique career story. Therefore, it offers resumes that focus on your individual achievements and skills. There are various resume writing services in the market to choose from. But what makes ResumeEdge different from the others is the team of proficient and veteran resume writers. Most of the resume writing services present online are small companies with a team of one or two individuals. However, this is not the case with ResumeEdge. The company owns a large team which means that there is always a skilled individual available to write a unique resume for every client. The writers take a critical look at your skills and past achievements to develop your resume from scratch. It is the best way to build your resume for your dream opportunity. Their main aim is to help you stand out from the crowd and secure the desired job. Now you must be thinking that resume writing services are expensive, so is it worth spending money on such a service? Well, this is not the case with ResumeEdge. The company understands the importance of the right pricing. Therefore, it offers a choice of plans to its clients so that they can choose the packages that best suit their budget and needs. Moreover, it also offers resume editing services, so if clients just want some editing to their current resumes, they do not have to think twice before approaching ResumeEdge. They say that “The first impression is the last impression,” and it is true. You only get a single chance to make that perfect first impression, and you should never risk it. Therefore, it is worth investing in a professional resume writing service to give your best shot in getting your dream job. Now put an end to the struggle of making a resume by visiting the company website. The price starts at only $100 and varies according to the package you choose. Contact ResumeEdge.com support@resumeedge.com Content Disclaimer: The above review statements are those of the sponsor (Source of content) and do not necessarily reflect the official policy, position or views of the content publisher. The content distribution company is therefore not responsible for the content and its authenticity and legal standing of the above subject matter. Each individual is required to exercise its content when making a purchase from the above offer. The information does not constitute advice or an offer to buy. Any purchase made from the above press release is made at your own risk. Editorial merit of this content is subject to news publisher and its downstream partners. Consult an expert advisor/health and professional advisor before any such purchase. Any purchase made from this link is subject to the final terms and conditions of the website's selling as mentioned in the above as source. The content publisher and its downstream distribution partners do not take any responsibility directly or indirectly. If you have any complaints or copyright issues related to this article, kindly contact the company this news is about. DISCLAIMER of Liability. IN NO EVENT SHALL OUR PR COMPANY BE LIABLE OR RESPONSIBLE TO YOU OR ANY OTHER PERSON FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, OR EXEMPLARY DAMAGES OF ANY KIND, INCLUDING WITHOUT LIMITATION, LOST PROFITS OR LOST OPPORTUNITIES, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES IN ADVANCE AND REGARDLESS OF THE CAUSE OF ACTION UPON WHICH ANY SUCH CLAIM IS BASED, INCLUDING, WITHOUT LIMITATION, ANY CLAIM ARISING OUT OF OR IN CONNECTION WITH ANY OF THE CONTENT, INCLUDING, WITHOUT LIMITATION, AUDIO, PHOTOGRAPHS, AND VIDEOS, OR OF THE ACCURACY, RELIABILITY, OR LEGALITY OF ANY STATEMENT MADE IN OR OMITTED FROM ANY advertisement, sponsorship, endorsement, testimonial, opinion, or other product-related or service-related statement or review appearing in the Websites or in ANY post or article distributed via the Websites.
LONDON — Now that the Royal Family has said farewell to Prince Philip, attention will turn to Queen Elizabeth II’s 95th birthday on Wednesday and, in coming months, the celebrations marking her 70 years on the throne. This combination of events is reminding the United Kingdom that the reign of the queen, the only monarch most of her subjects have ever known, is finite. That has triggered speculation about how long she will remain on the throne, what the monarchy will look like in the future and, for some, even whether it should continue to exist. “The queen is certainly moving now into the twilight of her reign and a new phase of her reign,’’ said Anna Whitelock, director of the Centre for the Study of Modern Monarchy at Royal Holloway, University of London. “She now is a widow, and it remains to be seen how she’s going to respond to that.’’ While most observers say the queen is unlikely to abdicate given her lifelong commitment to public service, she has already started to turn over more responsibilities to Prince Charles, 72, her eldest son. That process is likely to accelerate following Philip’s death. Charles’ increased role began gradually, when the queen began cutting back on long-haul flights, resulting in Charles taking her place at a 2013 Commonwealth Heads of Government meeting in Sri Lanka. Then in 2017, he represented the queen at the annual Remembrance Day ceremony marking the end of World War I, laying the monarch’s wreath at the foot of the Cenotaph in London. It was the first time the queen hadn’t performed the solemn ritual, other than when she was pregnant or out of the country. Since then, Charles has taken on an increasing number of public engagements and been named the queen’s designated successor as head of the Commonwealth, a voluntary association of 54 nations with links to the British Empire. “Symbolically, the transition towards the succession is already underway,” said Ed Owens, a historian and author of “The Family Firm, Monarchy, Mass Media and the British Public 1932-53.” “I anticipate that we’re going to see a lot more of Prince Charles in the next couple of years so that we, as a people, start to see him in his future role as king.” For now, the longest serving monarch in British history continues to reign. But she will do so without Philip, the man the queen called her “strength and stay,” a source of emotional support in her often lonely job. Her loss was underscored by Saturday’s funeral at St. George’s Chapel on the grounds of Windsor Castle, where the figure of a widow in black sitting alone offered a glimpse of the next solitary phase of the queen’s reign. “Constitutionally, Prince Philip’s death doesn’t change anything. But, of course, at a time when the queen is approaching her 95th birthday, she’s vulnerable and aging,’’ Whitelock said. “Clearly, Prince Philip’s death has begun this transition to the future and the beginning of the end of this phase of monarchy.” Questions about the end of the queen’s reign will also fuel the debate over the long-term future of the monarchy, seen by many as a symbol of national unity but by others as an obsolete vestige of the nation’s feudal history. The BBC received more than 100,000 complaints about its decision to pre-empt popular TV programs for round-the-clock coverage of Prince Philip’s death, the most it has ever received about a single programming decision. And while there is enormous respect for the queen, the same isn’t necessarily true for Charles and other members of the royal family, said Graham Smith, chief executive of Republic, which campaigns to replace the monarchy with an elected head of state. Philip’s death “serves as a reminder to an awful lot of people, who on the whole don’t think much about the monarchy from one day to the next, that change is coming,” Smith told the Express newspaper. The queen’s reign began with the death of her father, King George VI, on Feb. 6, 1952. She was formally crowned on June 2, 1953. During that ceremony, televised around the world, the queen promised to govern the United Kingdom and her other realms. Six years earlier, in a speech in South Africa, then-Princess Elizabeth made clear that her commitment was for life. “I declare before you all that my whole life, whether it be long or short, shall be devoted to your service and the service of our great imperial family to which we all belong,” she said. That is a pledge the queen intends to keep, said Robert Hardman, author of “Queen of the World,” which chronicles the monarch’s influence and stature around the globe. Even as she mourned last week, the queen attended a ceremony marking the retirement of her Lord Chamberlain, who organizes all ceremonial events for the palace, and continued to hold conversations with Commonwealth leaders. That shows she has no intention of emulating Queen Victoria, who retreated from public life when her husband, Prince Albert, died unexpectedly at the age of 42, Hardman told the BBC. “The signal she’s been putting out during the last week is that this is going to be business as usual, that duty comes before self,” Hardman said. “She will continue with all her duties because … she took a coronation oath and she’s sticking to it.” But she won’t be alone. While her popular grandson, Prince Harry, has stepped away from royal duties, the rest of the royals, backed by professional staff and advisers, are likely to rally round the queen and take on more tasks. Sustaining the institution will be the bedrock popularity of the Duke and Duchess of Cambridge, who have a reliable ability to connect with the public. The queen may also be helped by technology. During the pandemic, Elizabeth has connected with the public through a series of Zoom calls. The appearances, released by the palace and posted on social media, have allowed people to see the queen speaking to schoolchildren, volunteers and health service officials — smiling, joking and making canny observations in a more personal way than the scripted speeches that have dominated her public life. Last month, for example, she held a Zoom call with a group of children and scientists where she was asked about her meeting with the first man in space, Russian cosmonaut Yuri Gagarin. The monarch, who invited Gagarin to Buckingham Palace shortly after his historic flight in 1961, was asked what the pioneering spaceman was like. “Russian,” she replied with a smile. The audience chuckled. Just another day of working from home. “There’ll be a lot of emphasis as soon as the funeral is done on a return to normalcy. (For) the Royal Family, it will be the ‘Keep Calm and Carry On' sort of model, which they’ve been so good at promoting over the last 70, 80 years,'' Owens said, referring to the World War II-era adage. “They’ll want a quick return to the normal program of royal service.” Danica Kirka, The Associated Press
The European Union is seeking to encourage greater investment from Taiwan especially its semiconductor firms, the bloc's top diplomat in Taipei said on Tuesday, amid a global chip shortage that has impacted auto makers like Volkswagen. Tech powerhouse Taiwan, home to companies like Taiwan Semiconductor Manufacturing Co Ltd (TSMC), has become front and centre of efforts to resolve that shortfall, whose impact is now being felt in consumer electronics too. German Economy Minister Peter Altmaier wrote to Taiwan's government this year asking for help to ease tight chip supplies, and Europe is also encouraging more chip production at home.
Ace every interview with the perfect resumes from Skillroads.com.San Francisco, CA, April 20, 2021 (GLOBE NEWSWIRE) -- In the contemporary competitive era, no one wants to miss the chance of securing a dream job, and a well-developed resume is a key to it. A perfect resume is a must to make an excellent first impression on the recruiters. You need to make sure that the fastidious hiring managers see your best version. So, if you want a top-notch resume, Skillroads.com is the best resume writing company for you. What makes this company different from the others is its use of Artificial Intelligence to create a unique resume. Skillroads.com has integrated progressive technologies and experienced resume writers to deliver top-notch resumes to its clients. The company allows algorithms to investigate your professional interests, run career counselling and develop custom resumes. Skillroads.com is a professional and veteran resume writing service aimed at empowering the employment process. The company has an impressive success rate of 96.4%. The primary goal is to ensure that every client secures their dream job either with the personalized services provided by professionals or with AI resume builders. The company offers a wide range of application document creation services like creating a simple resume, LinkedIn Profile, and CV editing. Moreover, it also offers application job packages that include Cover Letter Writing + Resume/CV Writing + Resume/CV custom design + LinkedIn Profile editing. The company offers several packages of this type to meet client requirements. Still not sure about Skillroads.com? Worry not. The company also has two free options, which allow you to try the services first without making the payment. In this way, it lets you create a free resume with the help of an AI resume maker. Apart from that, you can also check your current resume with the Resume Review service without burning any money. The resume-making service of Skillroads.com is empowered by Artificial Intelligence which makes it the best in the market. Moreover, the company also has a team of skilled resume writers with experience in writing resumes in a wide range of industries. The resume writers create a resume from scratch and tailor it to your needs to help you get your desired job position. Skillroads.com takes the responsibility to ensure that all clients get satisfied final results. The use of AI helps to make sure that you get a striking and error-free resume. Moreover, in case of discontent, it provides three free revisions within a time period of 14 days to ensure customer satisfaction. Skillroads.com allows you to turn your resume into an effective marketing tool to showcase your skills and impress employers. It allows you to secure more chances to win the interview. Skillroads.com is the right place for you to get your perfect resume and get your dream job. The company offers a top-notch professional resume to grab the attention of fastidious recruiters. For more information visit the company website. So, what are you waiting for? With Skillroads.com, get your perfect resume and secure your dream job. Contact SkillRoads.com support@skillroads.com 1326 Larkin St, San Francisco CA 94109, United States Content Disclaimer: The above review statements are those of the sponsor (Source of content) and do not necessarily reflect the official policy, position or views of the content publisher. The content distribution company is therefore not responsible for the content and its authenticity and legal standing of the above subject matter. Each individual is required to exercise its content when making a purchase from the above offer. The information does not constitute advice or an offer to buy. Any purchase made from the above press release is made at your own risk. Editorial merit of this content is subject to news publisher and its downstream partners. Consult an expert advisor/health and professional advisor before any such purchase. Any purchase made from this link is subject to the final terms and conditions of the website's selling as mentioned in the above as source. The content publisher and its downstream distribution partners do not take any responsibility directly or indirectly. If you have any complaints or copyright issues related to this article, kindly contact the company this news is about. DISCLAIMER of Liability. IN NO EVENT SHALL OUR PR COMPANY BE LIABLE OR RESPONSIBLE TO YOU OR ANY OTHER PERSON FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, OR EXEMPLARY DAMAGES OF ANY KIND, INCLUDING WITHOUT LIMITATION, LOST PROFITS OR LOST OPPORTUNITIES, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES IN ADVANCE AND REGARDLESS OF THE CAUSE OF ACTION UPON WHICH ANY SUCH CLAIM IS BASED, INCLUDING, WITHOUT LIMITATION, ANY CLAIM ARISING OUT OF OR IN CONNECTION WITH ANY OF THE CONTENT, INCLUDING, WITHOUT LIMITATION, AUDIO, PHOTOGRAPHS, AND VIDEOS, OR OF THE ACCURACY, RELIABILITY, OR LEGALITY OF ANY STATEMENT MADE IN OR OMITTED FROM ANY advertisement, sponsorship, endorsement, testimonial, opinion, or other product-related or service-related statement or review appearing in the Websites or in ANY post or article distributed via the Websites.
The ‘Big Six’ clubs will be excluded from an emergency Premier League meeting on Tuesday to discuss a response to the proposals.
The retailer says the number of people in its stores in England and Wales is back to pre-pandemic levels.
Xu frequently uses the lion in his work to exemplify his faith in the rise of the Chinese nation.
In the past 30 days, more than 25,000 people tested positive compared to just 7,501 in January, among a population of 2.75 million, although there is no evidence linking sporting events to the surge.
Internationally respected corporate executive brings over 30 years of leadership in life sciences to BiotalysGhent, BELGIUM, April 20, 2021 (GLOBE NEWSWIRE) -- Biotalys Appoints Simon Moroney as Chairman of the Board Internationally respected corporate executive brings over 30 years of leadership in life sciences to Biotalys Ghent, BELGIUM – 20 April 2021 – Biotalys, an AgTech company focused on addressing food protection challenges to enable a more sustainable and safer food supply, is pleased to announce the appointment of Simon Moroney as Chairman of the Board, following the Company’s Annual General Meeting end of last week. Simon brings over 30 years of industry leadership and research experience to the Biotalys Board. From 1992 to 2019, he was co-founder and CEO of MorphoSys, a leading biotechnology company focused on the treatment of cancer and autoimmune diseases. At MorphoSys, Simon played a central role in establishing the company as a driving force in the field of therapeutic antibodies and led the company to a $239m initial public offering on the Nasdaq stock exchange in 2018. He currently sits on the board of Novartis as a non-executive Director. Simon has been recognized and awarded with the German Cross of the Order of Merit for his work and contribution to the biotechnology industry. “Simon is an eminent figure in the global life sciences community, and his appointment as Chairman of the Board demonstrates our ambition to establish Biotalys at the forefront of innovation in agricultural technology. Simon’s extensive experience and proven track record will be invaluable to our team as we continue to develop our pipeline of antibody-derived biocontrol solutions. On behalf of Biotalys and the Board of Directors, I warmly welcome Simon and look forward to drawing upon his strategic and operational judgment,” said Patrice Sellès, CEO of Biotalys. “I would also like to deeply thank Lieven De Smedt for his professional contribution as a consensus-building Chairman over the past six years and, in particular, for his active role in the capital rounds and his mentorship in building the company’s management team.” “I strongly believe that Biotalys has great potential to become an important force of innovation in the global AgTech sector, addressing the urgent need for more sustainable food production and offering effective alternatives to conventional crop protection products that are safer for the environment, grower and consumer,” added Simon Moroney, newly appointed Chairman of the Board at Biotalys. “I am excited to join as Chairman, where I believe my experience in both antibody technology and in building innovative companies from early stage through to commercialization leaves me well placed to guide the Company at this key phase in its development. I look forward to working closely with Patrice and the Biotalys leadership team as we continue to build and develop our pipeline of transformative biocontrol solutions.” Simon holds a D. Phil in Chemistry from the University of Oxford and has held positions in the Department of Pharmacology at the University of Cambridge, as Assistant Professor in the Chemistry Department, University of British Columbia and as Associate and Lecturer in the Chemistry Department of the ETH Zurich. Today’s announcement follows the recent submissions to the EU and US regulatory authorities of the registration dossier for the Company’s first protein-based biocontrol product, Evoca™ *, Biotalys’ first biofungicide which aims to provide fruit and vegetable growers with a novel mode of action to control key pathogens in selected crops. * Evoca™: Pending Registration. This product is not currently registered for sale or use in the European Union, the United States or elsewhere and is not being offered for sale. About Biotalys Biotalys is an Agricultural Technology (AgTech) company focused on addressing food protection challenges with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys has developed a strong and diverse pipeline of effective products with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and has raised €62.8 million (US$74,9 million) to date from Belgian and international specialised investors. The Company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com. For further information, please contact Toon Musschoot, Strategic Communications ManagerT: +32 (0)9 274 54 00E: Toon.Musschoot@biotalys.com Consilium Strategic CommunicationsAmber Fennell, Chris Gardner, Chris WelshT: +44 (0)203 709 5700E: Biotalys@consilium-comms.com
Geico has filed a data breach notice with the California attorney general’s office, admitting that fraudsters had stolen customers' driver's license numbers from its website.
Singer reshared photo on social media
Amsterdam/’s-Hertogenbosch, the Netherlands, 20 April 2021 In the period from 13 April 2021 until 19 April 2021 Van Lanschot Kempen has repurchased 46,885 of its own shares (depositary receipts for Class A ordinary shares). The shares were repurchased at an average price of €24.45 per share for a total amount of €1,146,315. These repurchases are part of the share buy-back programme for at most 400,000 of own shares, which was announced on 25 February 2021. The total number of shares repurchased to date is 274,607. More information, including a detailed overview of the repurchase transactions under this programme, is available on www.vanlanschotkempen.com/sharebuyback. Media Relations: +31 20 354 45 85; mediarelations@vanlanschotkempen.comInvestor Relations: +31 20 354 45 90; investorrelations@vanlanschotkempen.com About Van Lanschot Kempen Van Lanschot Kempen, a wealth manager operating under the Van Lanschot, Kempen and Evi brand names, is active in Private Banking, Asset Management and Merchant Banking, with the aim of preserving and creating wealth, in a sustainable way, for both its clients and the society of which it is part. Van Lanschot Kempen, listed at Euronext Amsterdam, is the Netherlands’ oldest independent financial services company with a history dating back to 1737. For more information, please visit vanlanschotkempen.com Disclaimer This press release does not constitute an offer or solicitation for the sale, purchase or acquisition in any other way or subscription to any financial instrument and is not a recommendation to perform or refrain from performing any action. This press release is a translation of the Dutch language original and is provided as a courtesy only. In the event of any disparities, the Dutch language version will prevail. No rights can be derived from any translation thereof. Attachment 210420 Share buy-back programme weekly press release
The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Wednesday, May 19, 2021. Due to the situation resulting from the Corona virus, the Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting with the possibility to attend in person or to be represented by a proxy will take place. ENTITLEMENT TO PARTICIPATE AND NOTICE Shareholders who wish to participate in the Meeting must (i) be recorded in the register of shareholders maintained by Euroclear Sweden AB on Monday, May 10, 2021, and (ii) notify the Company of their intention to attend the Meeting no later than Tuesday, May 18, 2021 by casting its advance vote in accordance with the instructions under the heading “Advance voting” below so that the advance voting form is received by the Company no later than that day. In order to be entitled to participate in the meeting, shareholders whose shares are registered in the name of a nominee must, in addition to announcing their intention to participate in the meeting, request that their shares be registered in their own name so that the shareholder is recorded in the register of shareholders as of 10 May 2021. Such registration may be temporary (so-called voting rights registration) and request for such registration shall be made to the nominee in accordance with the nominee’s routines at such time in advance as prescribed by the nominee. Voting rights registrations that have been made no later than the second banking day after 10 May 2021 will be taken into account when preparing the share register. There are 217,971,720 shares and votes in Active Biotech. The Company holds no treasury shares. ADVANCE VOTING The shareholders may exercise their voting rights at the Meeting by voting in advance, so called postal voting in accordance with section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of shareholders’ meetings in companies and other associations. A special form shall be used for advance voting. The form is available on the Company’s website www.activebiotech.com. The advance voting form is considered as the notification of attendance to the Meeting. The completed voting form must be submitted to the Company no later than Tuesday, May 18, 2021. The completed form shall be sent to Active Biotech AB (publ), Attn: Susanne Jönsson, Scheelevägen 22, SE-223 63 Lund, Sweden (mark the envelope “Annual General Meeting”). A completed form may also be submitted electronically to susanne.jonsson@activebiotech.com. If the shareholder votes in advance by proxy, a power of attorney shall be enclosed to the form. Proxy forms are provided at the Company’s website, www.activebiotech.com, and sent to shareholders that so request. If the shareholder is a legal entity, a certified copy of a registration certificate or corresponding document indicating the authorized signatories of the legal entity shall be enclosed to the form. The shareholder may not qualify the advance vote with special instructions or conditions. If so, the vote is invalid in its entirety. Further instructions and conditions is included in the form for advance voting. PROPOSED AGENDA 1. Election of Chairman of the Meeting 2. Election of one or two persons to verify the minutes 3. Preparation and approval of the voting list 4. Approval of the agenda for the Meeting 5. Determination of whether the Meeting has been duly convened 6. Presentation of the Annual Report and the Auditors’ Report, and the Consolidated Accounts and the Auditors’ Report for the Group7. Resolution concerning the adoption of the Income Statement and the Balance Sheet, and the Consolidated Income Statement and the Consolidated Balance Sheet8. Resolution concerning the disposition of the Company’s results pursuant to the adopted Balance Sheet9. Resolution on discharge from liability of the members of the Board of Directors and the CEO 10. Determination of the number of members and alternate members of the Board of Directors and the number of auditors and alternate auditors 11. Determination of fees payable to the Board of Directors and auditor12. Election of the Board of Directors, Chairman of the Board and auditor a) re-election of Michael Shalmi b) re-election of Uli Hacksell c) re-election of Peter Thelin d) re-election of Axel Glasmacher e) re-election of Aleksandar Danilovski f) re-election of Elaine Sullivan g) re-election of Michael Shalmi as chairman of the board h) re-election of KPMG AB as auditor 13. Presentation of the Board of Directors’ remuneration report for approval 14. Resolution concerning Election Committee 15. The Board of Director’s proposal regarding share issue authorization PROPOSED RESOLUTIONS Persons to approve the minutes (item 2) Magnus Svensson and Werner Burghard, or if one or both of them have an impediment to attend, the person or persons instead appointed by the Board of Directors, are proposed to be elected to approve the minutes. The task of approving the minutes also includes verifying the voting list and that the advance votes received are correctly stated in the minutes of the Meeting. Voting list (item 3) The voting list proposed for approval under item 3 on the agenda is the voting list prepared by the company, based on the shareholders’ register and advance votes received, and verified by the persons elected to verify the minutes. Disposition of the Company’s results (item 8) The Board of Directors proposes that no dividend is paid and that the Company’s accumulated loss shall be carried forward. Board of Directors, etc. (items 1 and 10 – 12) The Election Committee, comprising Michael Shalmi (Chairman of the Board), Mats Arnhög (MGA Holding), Per Colleen (Fourth Swedish National Pension Fund) and Peter Thelin proposes the following: Chairman of the Meeting: attorney-at-law Erik Sjöman or, if he has an impediment to attend, the person instead appointed by the Board of Directors. Number of members and alternate members of the Board of Directors: six ordinary members with no alternates. Fees payable to the Board of Directors: unchanged SEK 500,000 to the Chairman of the Board and SEK 200,000 to each of the other Board members who are not employed by the Company. A member of the Board who performs work for the Company outside the scope of the Board work may also receive remuneration on market terms for such work performed. Board of Directors: re-election of Michael Shalmi, Uli Hacksell, Peter Thelin, Axel Glasmacher, Aleksandar Danilovski and Elaine Sullivan. Chairman of the Board: re-election of Michael Shalmi. Number of auditors and alternate auditors: one auditor with no alternates. Fees payable to the auditor: in accordance with approved invoices within the scope of the tender. Auditors: re-election of KPMG AB. The proposal regarding auditor is in accordance with the recommendation by the Audit Committee. For further information on the board members proposed for re-election, reference is made to the Company’s website, www.activebiotech.com. Election Committee (item 14) The Election Committee proposes that the Meeting assigns the Chairman of the Board the task of convening an Election Committee, based on the ownership structure at the end of September 2021, comprising the Chairman of the Board and one member appointed by each of the three largest shareholders of the Company. The Election Committee shall remain in place until the following Election Committee has been appointed. If a member of the Election Committee no longer represents one of the three largest shareholders in the Company, the Election Committee is entitled to dismiss the member. In the event that a member of the Election Committee resigns or is dismissed, the Election Committee may appoint another member nominated by the major shareholders to replace such a member. The Election Committee shall perform its duties in accordance with the stipulations for Election Committees stated in the Swedish Code of Corporate Governance. Share issue authorization (item 15) The Board proposes that the Annual General Meeting resolves to grant authorization to the Board, for a period that does not extend past the date of the next Annual General Meeting, on one or several occasions, with or without pre-emptive rights for the shareholders, to resolve on the issue of new shares and/or convertibles entitling to conversion to shares. It shall also be possible to make such an issue resolution stipulating in-kind payment, the right to offset debt or other conditions. The number of shares issued, or which may arise through the conversion of convertibles issued with the support of the authorization, may correspond to not more than 30 percent of the total number of shares in the Company after utilization of the authorization. The purpose of the authorization is to enable the financing, commercialization and development of the Company’s projects and to provide flexibility in commercial negotiations relating to partnerships. QUESTIONS AND SHAREHOLDERS’ RIGHT TO REQUIRE INFORMATION If any shareholder should so request and the Board assesses that this can be done without significant damage to the Company, the Board of Directors and the CEO of the Company shall provide information about conditions that could affect the assessment of items on the agenda, the Company’s and subsidiaries’ financial position as well as the Company’s relationship to other group companies. A request for such information shall be made by e-mail to susanne.jonsson@activebiotech.com or by regular post to Active Biotech AB (publ), Attn: Susanne Jönsson, Scheelevägen 22, 223 63 Lund, Sweden no later than ten days prior to the Meeting, that is Sunday, May 9, 2021. The information is provided by being made available at the Company’s offices and the Company’s website, www.activebiotech.com, no later than Friday, May 14, 2021. Furthermore, the information will be sent within the same time period to the shareholder who so request and provide its postal address. DOCUMENTATION, ETC. The Annual Report, the Board of Directors’ remuneration report and other supporting resolution documentation will be presented by being held available at the Company’s premises at Scheelevägen 22 in Lund, Sweden, and on the Company’s website, www.activebiotech.com, not later than three weeks prior to the Meeting. The documents will be sent to shareholders who request a copy and specify their postal address. The register of shareholders for the Meeting is also made available at the Company’s premises. Processing of personal data For information about the processing of your personal data, please refer to https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. Active Biotech’s AB (publ) corporate registration number is 556223-9227 and its registered office is in Lund, Sweden. Lund, Sweden, April 2021 The Board of Directors of Active Biotech AB (publ) Attachment 210420_Notice Annual General Meeting
This victory on Monday helped CSK to jump from 4th position to 2nd position in the points table.
Hosts look to maintain momentum after their FA Cup semi-final win at the weekend
Everything you need to know ahead of the top-flight clash
All there is to know before the top-flight meeting
All the important info around the top-flight game
London's Francis Crick Institute was already a magnet for investors in the capital's so-called Knowledge Quarter, but the coronavirus pandemic has lifted interest in offices and laboratories dedicated to life sciences to a new level. Investors have been drawn into European real estate dedicated to life sciences, which spans sectors such as biomedical devices and pharmaceuticals, by an ageing population and strong academic research in the region. "Life sciences have never been more under the spotlight because of what we've all had to endure," Peter Ferrari, chief executive of real estate investor AshbyCapital, told Reuters.
SP Group A/S has set new sales record for a quarter. All our 28 productions plants around the world are up running and our six sales and service companies are working. We still do all we can to protect each other, our partners and our relatives during the Corona pandemic. Revenue was up by DKK 51.7 million to DKK 598.1 million in Q1 2021, or by 9.5 % relative to the year-earlier period. Operating income (EBITDA) for Q1 2021 was DKK 105.2 million, against DKK 87.9 million in Q1 2020 equal to a EBITDA margin of 17.6 %. Earnings before interest and tax (EBIT) came to DKK 68.8 million in Q1 2021, against DKK 53.8 million in Q1 2020. Profit before tax was DKK 67.5 million in Q1 2021, against DKK 50.2 million in Q1 2020 equal to a EBT margin of 11.3 %. There was a positive cash inflow from operating activities of DKK 66.3 million in Q1 2021, against DKK 79.6 million in Q1 2020. Net interest-bearing debt (NIBD) amounted to DKK 702.4 million at 31 March 2021, against DKK 853.3 million at 31 March 2020. At 31 December 2020, NIBD was DKK 686.1 million. NIBD was 1.9 times LTM EBITDA. Due to the spread of the Corona virus and the actions taken by authorities, our level of activities and cash flows in the coming months are still subject to great uncertainty.Due to the very positive development in Q1 with high growth and good product mix, the outlook for FY 2021 has been changed:We are now expecting a growth in revenue of 4-12 % (previously 3-10 %)A EBITDA margin of 16-18 % (previously 16-17 %)A EBT margin of 9-12 % (previously 9-10 %). Statement by CEO Frank Gad: “Despite the Corona pandemic, global turbulence, uncertain market prospects and volatile prices of raw materials, we have increased our sales and EBITDA again in Q1. The first quarter of 2021 marks our best quarter ever in terms of both top and EBITDA lines.” Our interim report for Q1 2021 will be released on 26 May 2021 - as previously announced. Attachment Meddelelse nr. 28 - Trading Update - ENG - 20 04 21